Comparison of clinical outcomes of oral erythroleukoplakia treated with photodynamic therapy using either light-emitting diode or laser light
- PMID: 19816916
- DOI: 10.1002/lsm.20841
Comparison of clinical outcomes of oral erythroleukoplakia treated with photodynamic therapy using either light-emitting diode or laser light
Abstract
Background and objectives: Topical 5-aminolevulinic acid-mediated photodynamic therapy (topical ALA-PDT) using a 635-nm light-emitting diode (LED) light is an effective treatment modality for oral verrucous hyperplasia. This study tested whether topical ALA-PDT using either the LED or laser light was also an effective treatment modality for oral erythroleukoplakia (OEL) lesions.
Study design/materials and methods: In this prospective but non-randomized study, 20 OEL lesions were treated with topical ALA-PDT using the 635-nm LED light and 26 OEL lesions were treated with topical ALA-PDT using the 635-nm laser light. The difference in clinical outcomes was compared between the two groups by Fisher exact test.
Results: We found that the 20 LED light-treated OEL lesions showed complete response (CR) in 17 and partial response (PR) in 3. The 17 CR OEL lesions required an average of 3.7 (range, 2-7) treatments of ALA-PDT to achieve CR of the lesions. The 26 laser light-treated OEL lesions showed CR in 25 and PR in 1. The 25 CR OEL lesions needed an average of 3.3 (range, 2-6) treatments of ALA-PDT to achieve CR of the lesions. There was no significant difference in PDT outcomes between the 20 LED light-treated and 26 laser light-treated OEL lesions (P = 0.303). When the 42 CR OEL lesions were pooled together, we found that smaller lesions (greatest diameter <1.5 cm) and lesions with thinner surface keratin (keratin layer < or =30 microm) needed significantly fewer mean treatment number of PDT to achieve a CR than the larger lesions (P = 0.000) and lesions with thicker surface keratin (P = 0.000), respectively.
Conclusions: Topical ALA-PDT using either the LED or laser light is an effective treatment modality for OEL lesions. There is no significant difference in clinical outcomes of OEL lesions treated with PDT using either the LED or laser light.
Copyright 2009 Wiley-Liss, Inc.
Similar articles
-
Successful treatment of oral verrucous hyperplasia and oral leukoplakia with topical 5-aminolevulinic acid-mediated photodynamic therapy.Lasers Surg Med. 2005 Aug;37(2):114-22. doi: 10.1002/lsm.20214. Lasers Surg Med. 2005. PMID: 16037967
-
Photodynamic therapy outcome for oral verrucous hyperplasia depends on the clinical appearance, size, color, epithelial dysplasia, and surface keratin thickness of the lesion.Oral Oncol. 2008 Jun;44(6):595-600. doi: 10.1016/j.oraloncology.2007.08.016. Epub 2008 Jan 18. Oral Oncol. 2008. PMID: 18203648
-
Topical photodynamic therapy is very effective for oral verrucous hyperplasia and oral erythroleukoplakia.J Oral Pathol Med. 2010 Sep;39(8):624-30. doi: 10.1111/j.1600-0714.2010.00935.x. J Oral Pathol Med. 2010. PMID: 21054548
-
Efficacy of Aminolevulinic Acid Mediated Photodynamic Therapy in the Treatment of Oral Premalignant Lesions: A Systematic Review.Asian Pac J Cancer Prev. 2024 Sep 1;25(9):2971-2978. doi: 10.31557/APJCP.2024.25.9.2971. Asian Pac J Cancer Prev. 2024. PMID: 39342573 Free PMC article.
-
Treatment of anogenital condylomata acuminata with topical photodynamic therapy: report of 14 cases and review.Int J Infect Dis. 2010 Sep;14 Suppl 3:e280-2. doi: 10.1016/j.ijid.2009.11.031. Epub 2010 Mar 25. Int J Infect Dis. 2010. PMID: 20346722 Review.
Cited by
-
Photodynamic therapy with light-emitting diode arrays producing different light fields induces apoptosis and necrosis in gastrointestinal cancer.Front Oncol. 2022 Dec 16;12:1062666. doi: 10.3389/fonc.2022.1062666. eCollection 2022. Front Oncol. 2022. PMID: 36591528 Free PMC article.
-
Early-Phase Interventional Trials in Oral Cancer Prevention.Cancers (Basel). 2021 Jul 30;13(15):3845. doi: 10.3390/cancers13153845. Cancers (Basel). 2021. PMID: 34359746 Free PMC article. Review.
-
A phase I trial of aminolevulinic acid-photodynamic therapy for treatment of oral leukoplakia.Oral Oncol. 2013 Sep;49(9):970-976. doi: 10.1016/j.oraloncology.2013.05.011. Epub 2013 Jul 8. Oral Oncol. 2013. PMID: 23845699 Free PMC article. Clinical Trial.
-
RUNX3 confers sensitivity to pheophorbide a-photodynamic therapy in human oral squamous cell carcinoma cell lines.Lasers Med Sci. 2015 Feb;30(2):499-507. doi: 10.1007/s10103-013-1350-1. Epub 2013 May 23. Lasers Med Sci. 2015. PMID: 23700080
-
Photodynamic therapy in oral cancer: a review of clinical studies.Med Oncol. 2023 Feb 7;40(3):91. doi: 10.1007/s12032-023-01949-3. Med Oncol. 2023. PMID: 36749489 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials